Q1 2023 Results

April 27, 2023

Bristol Myers Squibb™

Forward Looking Statements and Non-GAAP Financial Information

This presentation contains statements about Bristol-Myers Squibb Company's (the "Company") future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Actual results may differ materially from those expressed in, or implied by, these statements as a result of various factors, including, but not limited to, (i) new laws and regulations, (ii) our ability to obtain, protect and maintain market exclusivity rights and enforce patents and other intellectual property rights, (iii) our ability to achieve expected clinical, regulatory and contractual milestones on expected timelines or at all, (iv) difficulties or delays in the development and commercialization of new products, (v) difficulties or delays in our clinical trials and the manufacturing, distribution and sale of our products, (vi) adverse outcomes in legal or regulatory proceedings, (vii) risks relating to acquisitions, divestitures, alliances, joint ventures and other portfolio actions and (viii) political and financial instability, including changes in general economic conditions. These and other important factors are discussed in the Company's most recent annual report on Form 10-K and reports on Forms 10-Q and 8-K. These documents are available on the U.S. Securities and Exchange Commission's website, on the Company's website or from Bristol-Myers Squibb Investor Relations. No forward-looking statements can be guaranteed.

In addition, any forward-looking statements and clinical data included herein are presented only as of the date hereof. Except as otherwise required by applicable law, the Company undertakes no obligation to publicly update any of the provided information, whether as a result of new information, future events, changed circumstances or otherwise.

This presentation includes certain non-generally accepted accounting principles ("GAAP") financial measures that we use to describe the Company's performance. The non-GAAP financial measures are provided as supplemental information and are presented because management has evaluated the Company's financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the Company's baseline performance, supplement or enhance management's, analysts' and investors' overall understanding of the Company's underlying financial performance and trends and facilitate comparisons among current, past and future periods. This presentation also provides certain revenues and expenses excluding the impact of foreign exchange ("Ex-FX"). We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. Ex-FX financial measures are not accounted for according to GAAP because they remove the effects of currency movements from GAAP results.

The non-GAAP information presented herein provides investors with additional useful information but should not be considered in isolation or as substitutes for the related GAAP measures. Moreover, other companies may define non-GAAP measures differently, which limits the usefulness of these measures for comparisons with such other companies. We encourage investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure. An explanation of these non-GAAP financial measures and a reconciliation to the most directly comparable financial measure are available on our website at www.bms.com/investors.

Also note that a reconciliation of forward-looking non-GAAP gross margin, non-GAAP operating expenses and non-GAAP tax rate is not provided because a comparable GAAP measure for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. Namely, we are not, without unreasonable effort, able to reliably predict the impact of the unwind of inventory purchase price adjustments, accelerated depreciation and impairment of property, plant and equipment and intangible assets, and stock compensation resulting from acquisition-related equity awards, or currency exchange rates. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results.

Bristol Myers Squibb™

Q1 2023 Results

Giovanni Caforio, MD

Chairman of the Board
and Chief Executive Officer

Q1 2023 Performance

Strong Commercial Execution

Global Net Sales

Q1:~$11.3B (3%) YoY; (1%) Ex-FX*

In-Line Brands & New Product Portfolio:

Q1:~$9.3B +8% YoY; +10% Ex-FX*

New Product Performance



Revenues **more than doubled** vs prior year

Strong Financial Execution

Earnings Per Share (EPS)

Q1: GAAP **$1.07,** +81% YoY

Non-GAAP* **$2.05,** +5% YoY

2023 Guidance

Total Sales[1]*
~2% YoY Growth

Increased GAAP EPS*	$4.10 - $4.40
Affirmed Non-GAAP EPS*	$7.95 - $8.25

Reflects continued top & bottom-line growth

[1]Sales growth on reported & Ex-FX* basis
*See "Forward-Looking Statements and Non-GAAP Financial Information"

Near-term Catalysts Across Diversified Portfolio

2023 Key Milestones

Opdivo (+/- Yervoy)	Early Stage: ☐ Neo-adjuvant NSCLC Ph3 (CM-816) approval in EU
	Metastatic ☐ 1L mCRPC Ph3 (CM-7DX)
Opdualag	☐ 1L NSCLC Ph2
repotrectinib	☐ ROS1+ NSCLC (TRIDENT-1) U.S. filing
Abecma	✓ 3-5L MM Ph3 (KarMMa-3) filing ☐ Initiation NDMM Ph3 (KarMMa-9)
Breyanzi	☐ 2L TE LBCL EU approval ✓ 3L+ CLL Ph1/2 (TRANSCEND-CLL) ☐ 3L+ FL Ph2 (TRANSCEND-FL)
iberdomide	✓ Initiation of pivotal post-transplant maintenance H2H vs Revlimid
Reblozyl	☐ 1L MDS (COMMANDS) U.S. filing
Sotyktu	✓ Mod-to-severe PsO EU approval ✗ CD Ph2 (IM011-023)[1] ☐ UC Ph2 (IM011-127)
LPA_1 Antagonist	☐ Initiation IPF Ph3 ☐ PPF Ph2 (IM027-040)
Camzyos	☐ oHCM EU approval[2]
LIBREXIA (milvexian)	✓ Initiation Ph3 program[3]

2024/2025 Key Milestones

Opdivo (+/- Yervoy)	Metastatic: ☐ 1L HCC Ph3 (CM-9DW) ☐ 1L+ MSI High CRC Ph3 (CM-8HW)
	Early Stage: ☐ Peri-adj NSCLC Ph3 (CM-77T) ☐ Peri-adj MIBC Ph3 (CM-078) ☐ Adj HCC Ph3 (CM-9DX) ☐ Stage III Unresectable NSCLC Ph3 (CM-73L) ☐ Adj NSCLC Ph3 (ANVIL, co-op group)
Opdualag	☐ 1L HCC Ph2 ☐ 2L+ HCC Ph2 ☐ 2L/3L+ MSS mCRC Ph3
alnuctamab BCMA TCE	☐ Initiation MM Ph3
Reblozyl	☐ 1L MF Ph3 (INDEPENDENCE)
cendakimab	☐ EoE Ph3
Sotyktu	☐ PsA Ph3
Zeposia	☐ CD maintenance Ph3 (YELLOWSTONE)

[1]CD PoC not achieved; awaiting higher dose UC Ph2 data to inform future IBD development plans; [2]EU CHMP Positive Opinion; [3]SSP, ACS, AF trials conducted by Janssen

Milestones represent data readouts unless otherwise specified; subject to positive registrational trials and health authority approval

New Product Portfolio Significantly De-Risked with Important Catalysts Ahead

Key Milestones

$10B - $13B
Risk-Adjusted Sales



2025

Beyond

- Camzyos nHCM
- Sotyktu SLE
- Opdualag 1L NSCLC
- Opdualag Adj. Mel
- Opdualag 2L+ MSS CRC

Planned Next 1-2 Years

- ✓ Breyanzi 3L+ CLL
- Breyanzi 3L+ iNHL
- Reblozyl MF
- Sotyktu PsA
- Zeposia CD

Milestones Already Delivered that De-Risk 2025-2030 and Beyond

- ✓ Zeposia MS
- ✓ Reblozyl 2L TD MDS
- ✓ Breyanzi 3L+ LBCL
- ✓ Abecma 5L+
- ✓ Zeposia UC
- ✓ Camzyos oHCM
- ✓ Sotyktu PsO
- ✓ Opdualag 1L Mel FDC
- ✓ Breyanzi 2L LBCL
- ✓ Abecma 3-5L
- ✓ Reblozyl 1L MDS
- ✓ Onureg AML maint.

$25B+
Non-Risk Adjusted*



CAMZYOS™
Opdualag™
SOTYKTU™
Reblozyl®
Breyanzi®
once-daily ZEPOSIA®
Abecma®

2030

Milestones represent data readouts unless otherwise specified;
subject to positive registrational trials and health authority approval

*Non-risk adjusted revenue potential
**Other includes: Abecma, Onureg, Inrebic, and Opdualag
Financial projections may contain non promoted sales, BMS promotes only according to label

Bristol Myers Squibb™

Q1 2023 Results

David Elkins

Executive Vice President
and Chief Financial Officer

Strong Total Company Performance

Total Company Sales ~$11.3B
(3%) YoY, (1%) Ex-FX*



$B	Q1 Net Sales[1]	YoY %	Ex-FX* %
Total Company	$11.3	(3%)	(1%)
In-Line Products	*$8.6*	*+4%*	*+6%*
New Product Portfolio	*$0.7*	**	**
In-Line Products & New Product Portfolio	$9.3	+8%	+10%
Recent LOEs[2]	$2.0	(34%)	(33%)

[1]Amounts may not add due to rounding
[2]Recent LOE Brands = Revlimid & Abraxane

*See "Forward-Looking Statements and Non-GAAP Financial Information"
**In excess of +100%

New Product Portfolio Sales Performance

Revenues more than doubled vs prior year



+12% or +11% Ex-FX* growth vs prior quarter



*See "Forward-Looking Statements and Non-GAAP Financial Information"

Q1 2023 Solid Tumor Product Summary

Q1 Global Net Sales

	$M	YoY %	Ex-FX* %
OPDIVO (nivolumab)	$2,202	+15%	+17%
YERVOY (ipilimumab)	$508	(1%)	+2%
Opdualag (nivolumab and relatlimab-rmbw)	$117	**	**
Abraxane	$239	+12%	+14%

**In excess of +100%

Opdivo

- U.S. growth driven by demand in 1L lung, upper GI indications & adj. bladder cancer
- Ex-U.S. growth from 1L lung & upper GI indications

Opdualag

- 3rd approved I-O agent; potential to be a new SOC in 1L melanoma
- U.S. growth driven by strong demand; >20% market share[1] in 1L melanoma

[1]Source: BMS Internal Analysis
*See "Forward-Looking Statements and Non-GAAP Financial Information"

Q1 2023 Cardiovascular Product Summary

Q1 Global Net Sales

	$M	YoY %	Ex-FX* %
Eliquis apixaban	$3,423	+7%	+8%

Best-in-class & leading OAC within category

- U.S. robust underlying demand strength
- Ex-U.S. continues to be #1 OAC in key international markets; impacted by some generic entry (UK & Canada) & pricing measures

	$M	YoY %	Ex-FX* %
CAMZYOS™ (mavacamten) 2.5, 5, 10, 15mg capsules	$29	---	---

First-in-class myosin inhibitor

- U.S. increase in total treated & commercial dispensed patients
  - VALOR: U.S. PDUFA date June 16, 2023
- EU CHMP Positive Opinion in oHCM; approval expected mid-year

	As of Dec 31, 2022[1]	As of March 31, 2023[1]
REMS Certified HCPs	~2600	~3200
Patients in hub	~1800	~2700
Patients on commercial drug	~900	~1500

[1]Source: BMS Internal Analysis

*See "Forward-Looking Statements and Non-GAAP Financial Information"

Q1 2023 Hematology Product Summary

Q1 Global Net Sales[1]

	$M	YoY %	Ex-FX* %
Revlimid (lenalidomide) capsules	$1,750	(37%)	(37%)
Pomalyst (pomalidomide) capsules	$832	+1%	+2%
SPRYCEL dasatinib 100 mg tablets	$429	(11%)	(9%)
Reblozyl (luspatercept-aamt) for injection 25mg + 75mg	$206	+32%	+33%
Abecma (idecabtagene vicleucel)	$147	**	**
Breyanzi (lisocabtagene maraleucel)	$71	+61%	+66%
ONUREG (azacitidine) tablets	$34	+48%	+52%
INREBIC (fedratinib) capsules 100mg	$25	+39%	+39%

**In excess of +100%

Revlimid - Impact from Gx entry; FY 2023 revenue projection of ~$6.5B

Pomalyst - Growth driven by demand for triplet-based regimens in earlier lines & favorable buying patterns ex-U.S.

Reblozyl

- U.S. demand growth & progress in patient adherence
- Continued expansion in international markets based on reimbursement timing

Abecma - Strong demand supported by increased manufacturing capacity

- KarMMa-3: U.S. PDUFA date December 16, 2023; filed in EU & Japan

Breyanzi - Strong 2L/3L+ demand supported by increased manufacturing capacity

- EU CHMP Positive Opinion in 2L LBCL

[1]Empliciti grouped in Mature & Other Brands
*See "Forward-Looking Statements and Non-GAAP Financial Information"

Q1 2023 Immunology Product Summary

Q1 Global Net Sales

	$M	YoY %	Ex-FX* %
ORENCIA (abatacept)	$764	(4%)	(1%)
ZEPOSIA (ozanimod) 0.92 mg capsules	$78	**	**

**In excess of +100%

	$M	YoY %	Ex-FX* %
SOTYKTU (deucravacitinib) 6 mg tablets	$16	---	---

Zeposia

- Growth from demand in MS & expanding contribution from UC
- Continued focus on improving formulary access
- Expansion in international markets based on reimbursement timing

First-in-class selective allosteric TYK2 inhibitor

- U.S. continued strong early adoption; significant demand growth in Q1
- Focused on driving demand to enable broader access in 2024

	As of Dec 31, 2022[1]	As of March 31, 2023[1]
Volume	>2000 TRx Equivalent	>9500 TRx Equivalent[2]
Market Share[3]	~25-30%	Mid-30s%
Source of Business	• Systemic-naïve (~1/3) • Otezla-experienced (~1/3) • Biologic-experienced (~1/3)	Consistent with prior quarter

[1]Source: BMS Internal Analysis
[2]Cumulative TRx equivalent since launch
[3]Market share of written oral prescriptions in NBRx sourced from BrandImpact *See "Forward-Looking Statements and Non-GAAP Financial Information"

Q1 2023 Financial Performance

$ in billions, except EPS	US GAAP		Non-GAAP*	
	Q1 2023	Q1 2022	Q1 2023	Q1 2022
Total Revenues, net	11.3	11.6	11.3	11.6
Gross Margin %	77.4%	78.8%	77.8%	79.2%
Operating Expenses[1]	4.1	4.1	4.0	4.0
Acquired IPR&D	0.1	0.3	0.1	0.3
Amortization of Acquired Intangibles	2.3	2.4	-	-
Effective Tax Rate	18.2%	23.9%	15.5%	15.9%
Diluted EPS	1.07	0.59	2.05	1.96
Diluted Shares Outstanding *(# in millions)*	2,113	2,164	2,113	2,164
Diluted EPS Impact from Acquired IPR&D[2]	(0.01)	(0.10)	(0.01)	(0.10)

[1]Operating Expenses = MS&A and R&D
[2]Comprises the net impact from Acquired IPRD & Licensing income
*See "Forward-Looking Statements and Non-GAAP Financial Information"

Balanced Approach to Capital Allocation

Cash flow from Operations $B



$B	Q1 2023
Total Cash*	~$9.3B
Total Debt	~$37.8B

Strong operating cash flow generation

Business Development

- Prioritize opportunities to further diversify portfolio & strengthen long-term outlook

Balance Sheet Strength

- Continued debt reduction
  - ~$1.6B in debt repayments in Q1
- Maintain strong investment-grade credit rating

Returning Cash to Shareholders

- Continued annual dividend growth**
  - 14th consecutive dividend increase
- Opportunistic share repurchase
  - ~$7B remaining authorization

*Cash includes cash, cash equivalents and marketable debt securities
**Subject to Board approval

2023 Guidance

	US GAAP*		Non-GAAP*
	February (Prior)	April (Revised)	April (Affirm)
Total Revenues Reported Rates	~2% increase	No Change	~2% increase
Total Revenues Ex-FX	~2% increase	No Change	~2% increase
Revlimid	~$6.5 billion	No Change	~$6.5 billion
Gross Margin %	~77%	No Change	~77%
Operating Expenses[1]	Mid-single digit decline	No Change	Low-single digit decline
Tax Rate	~22%	~21%	~17%
Diluted EPS	$4.03 - $4.33	$4.10 - $4.40	$7.95 - $8.25

[1]Operating Expenses = MS&A and R&D, excluding Acquired IPR&D and Amortization of acquired intangibles
*See "Forward-Looking Statements and Non-GAAP Financial Information"

Bristol Myers Squibb™

Q1 2023 Results Q&A

Giovanni Caforio, MD
Chairman of the Board,
Chief Executive Officer

Chris Boerner, PhD
Executive VP,
Chief Operating Officer

David Elkins
Executive VP,
Chief Financial Officer

Samit Hirawat, MD
Executive VP,
Chief Medical Officer,
Global Drug Development

2023 Key News Flow

Asset	Timing
Opdivo EU approval in Neo-Adj. Lung EFS (CM-816)	Application under review
Opdivo 1L mCRPC Ph3 (CM -7DX)	2023
Opdualag Stage IV 1L NSCLC Ph2 (CA227-104)	YE 2023/2024
repotrectinib ROS1+ NSCLC (TRIDENT-1) filing	2023
Abecma 3-5L MM (KarMMa-3) filing	U.S. PDUFA December 16, 2023 Application under review in EU & Japan
Breyanzi EU approval in 2L LBCL (Transplant Eligible)	CHMP Positive Opinion
Breyanzi 3L+ CLL Ph1/2 (TRANSCEND-CLL)	Met primary endpoint in January 2023 Data at ASCO 2023
Breyanzi 2L & 3L+ FL Ph2 (TRANSCEND-FL)	2023

Asset	Timing
Reblozyl EU approval in NTD Beta-Thalassemia Associated Anemia	Approved in EU March 2023
Reblozyl 1L TD MDS Associated Anemia (COMMANDS) filing	Filing in 2023 Data at ASCO & EHA 2023
Sotyktu EU approval in mod-to-severe PsO POETYK PSO-1 & PSO-2	Approved in EU March 2023
Sotyktu Crohn's Disease Ph2 (LATTICE-CD)	PoC not achieved[1]
Sotyktu Ulcerative Colitis (higher dose) Ph2 (IM011-127)	2H 2023
LPA_1 antagonist Progressive Pulmonary Fibrosis (PPF) Ph2 (IM027-040)	2023
Camzyos EU approval in symptomatic obstructive HCM (EXPLORER-HCM)	CHMP Positive Opinion
Camzyos U.S. approval in obstructive HCM SRT eligible (VALOR)	U.S. PDUFA June 16, 2023

[1]CD PoC not achieved; awaiting higher dose UC data to inform future IBD development plan
Milestones represent data readouts unless otherwise specified; subject to positive registrational trials and health authority approval

Q1 2023 Opdivo Sales Mix

OPDIVO™ (nivolumab)
INJECTION FOR INTRAVENOUS USE 10 mg/mL

U.S. Sales Mix



Ex-U.S. Sales Mix



NSCLC RCC Melanoma Upper GI All others

Note: percentages are approximate

Q1 2023 Eliquis NBRx/TRx Share

Eliquis apixaban



Rx Source: IQVIA

Our ESG Achievements and Looking Ahead[1]

ESG Strategy

- ✓ Initiated **ESG materiality assessment**
- ✓ Assessment is **global** and follows **double materiality** best practices
- ✓ ESG operating model to further **align with company strategy**

Inclusion & Diversity

- ✓ Executive representation:
  - **6.1%** Black/African American (VP+ in the U.S.)
  - **6.1%** Hispanic/Latino (VP+ in the U.S.)
  - **49%** of executives are women
- ✓ **58%** clinical trial sites in diverse metro areas
- ✓ **$1B** global spend on diverse-owned businesses

Health Equity

- ✓ Nearly **$100 million** in distributed funding from BMS has reached more than **10 million** people
- ✓ *BMS Foundation has distributed:
  - **$100 million** to establish Robert A. Winn Diversity in Clinical Trials Award Program
  - **$45 million** across 32 grants to advance **health equity** in cancer, cardiovascular disease, and immunology

Environment

- ✓ Exceeded GHG emission reduction target from **2% to 6%** for 2022
- ✓ Exceeded waste to landfill target from **5% to 37%** for 2022

Looking Ahead

ESG materiality assessment results will be shared later this year

Progress on expanded **2025 I&D goals** announced earlier this year

Announced distribution of an additional $10 million[2] in grant funding to 17 U.S. organizations focused on addressing social determinants of health

Reporting Task Force on Climate Related Financial Disclosures (TCFD) metrics for the first time later this year

[1]For more information on our Governance profile, including Board composition and oversight of strategy and key enterprise risks, as well as the ESG goals and commitments, please see our 2023 Proxy Statement and our 2022 ESG Report to be published later this year; [2]This forms part of the original $150M commitment from each of BMS and the BMS Foundation; *Bristol Myers Squibb Foundation (independent charitable organization)

Clinical Development Portfolio – Phase I & II

Data as of April 27th, 2023

Phase I

✦ AHR Antagonist*^	Solid Tumors
✦ Anti-CCR8^	Solid Tumors
✦ Anti-ILT4^	Solid Tumors
✦ Anti-NKG2A^	Solid Tumors
✦ AR-LDD	Solid Tumors
✦ Claudin 18.2 ADC	Solid Tumors
✦ CD3xPSCA Bispecific*	Solid Tumors
✦ DGK Inhibitor	Solid Tumors
✦ JNK Inhibitor	Solid Tumors
✦ MAGE A4/8 TCER*	Solid Tumors
✦ NME	Solid Tumors
✦ SHP2 Inhibitor^	Solid Tumors
✦ TGFβ Inhibitor^	Solid Tumors
✦ TIGIT Bispecific	Solid Tumors
OPDIVO	Solid Tumors
OPDIVO+YERVOY	Solid Tumors
✦ alnuctamab BCMA TCE	RR Multiple Myeloma
✦ Anti-SIRPα	Hematologic Malignancies
✦ BCMA ADC^	RR Multiple Myeloma
✦ BCMA NKE	RR Multiple Myeloma
✦ BET Inhibitor (CC-90010)^	Hematologic Malignancies
✦ CD33 NKE	RR Multiple Myeloma
✦ CD47xCD20	Non-Hodgkin's lymphoma
✦ CK1α Degrader	Hematologic Malignancies
✦ GPRC5D CAR T	RR Multiple Myeloma
✦ GSPT1 CELMoD (CC-90009)^	RR Acute Myeloid Leukemia
A/I CELMoD (CC-99282)^	1L Diffuse Large B-cell Lymphoma
OPDIVO	Hematologic Malignancies
✦ FXIa Inhibitor	Thrombotic Disorders
✦ Anti-CD40	Autoimmune Disease
✦ CD19 NEX T	Severe Refractory Systemic Lupus Erythematosus
✦ RIPK1 Inhibitor	Autoimmune Disease
✦ IL2-CD25	Autoimmune Disease
✦ PKCθ Inhibitor	Autoimmune Disease
afimetoran (TLR 7/8 Inhibitor)	Cutaneous Lupus Erythematosus
✦ Anti-Tau*	Neuroscience
✦ BTK Inhibitor	Neuroscience
✦ eIF2b Activator	Neuroscience
✦ FAAH/MGLL Dual Inhibitor	Neuroscience

Phase II

✦ Anti-CTLA-4 NF Probody® Therapeutic	Solid Tumors
✦ Anti-Fucosyl GM1^	Solid Tumors
✦ Anti-IL-8^	Solid Tumors
✦ Anti-TIGIT^	Solid Tumors
✦ BET Inhibitor (CC-90010)^	Solid Tumors
✦ farletuzumab ecteribulin	Solid Tumors
✦repotrectinib	ROS1 NSCLC
	NTRK PanTumor
OPDIVO	2L Colorectal Cancer
	Pan-Tumor TMB High
	Solid Tumors
OPDIVO+YERVOY	2L Metastatic Castration-Resistant Prostate Cancer
	Solid Tumors
nivolumab+relatlimab	Stage IV 1L Non-Small Cell Lung Cancer
	1L, 2L Hepatocellular carcinoma
✦ A/I CELMoD (CC-99282)^	RR Non-Hodgkin's Lymphoma
✦ BET Inhibitor (BMS-986158)	Hematologic Malignancies
ABECMA (ide-cel)	1-4L+ Multiple Myeloma
BREYANZI (liso-cel)	3L+ Chronic Lymphocytic Leukemia (CLL)
	3L+ Follicular Lymphoma (FL)
	3L+ Marginal Zone Lymphoma (MZL)
	3L+ Mantle Cell Lymphoma (MCL)
REBLOZYL	A-Thalassemia
ONUREG	Low- or Intermediate-risk Myelodysplastic Syndrome
✦Cardiac Myosin Inhibitor (MYK-224)	Obstructive Hypertrophic Cardiomyopathy
✦ danicamtiv	Genetic Dilated Cardiomyopathy
CAMZYOS	Heart Failure with preserved Ejection Fraction (HFpEF)
✦ afimetoran (TLR 7/8 Inhibitor)	Systemic Lupus Erythematosus
✦ TYK2 Inhibitor (BMS-986322)	Moderate-to-Severe Psoriasis
SOTYKTU	Crohn's Disease
	Discoid Lupus Erythematosus
	Alopecia Areata
	Ulcerative Colitis
✦ HSP47	Non-alcoholic Steatohepatitis (NASH)
✦ LPA1 Antagonist	Pulmonary Fibrosis

* Partner-run study

✦ NME leading indication

^ Trials exploring various combinations

Oncology | Hematology | CV | Fibrosis | Neuroscience | Immunology

Clinical Development Portfolio – Phase III

Data as of April 27th, 2023

Phase III

✦ subcutaneous nivolumab + rHuPH20 (multi-indications)	2L Renal Cell Carcinoma
OPDIVO	Adjuvant Hepatocellular Carcinoma
	1L Metastatic Castration-Resistant Prostate Cancer
	Peri-adjuvant Muscle Invasive Urothelial Carcinoma
	Peri-adjuvant Non-Small Cell Lung Cancer
	Stage IB-IIIA Adjuvant NSCLC*
OPDIVO + YERVOY	1L Hepatocellular Carcinoma
	1L Bladder Cancer
	1L+ Microsatellite Instability High Colorectal Cancer
	Stage 3 Unresectable Non-Small Cell Lung Cancer
OPDUALAG	Adjuvant Melanoma
	2/3L+ Microsatellite Stable Metast. Colorectal Cancer
✦subcutaneous nivolumab + relatlimab + rHuPH20	1L Melanoma
✦ iberdomide	2L+ Multiple Myeloma
	Post-Transplant Maintenance Newly Diagnosed Multiple Myeloma
✦ mezigdomide (CC-92480)	2L+ Multiple Myeloma
INREBIC	Myelofibrosis previously treated with Ruxolitinib
REBLOZYL	1L TD Myelodysplastic Syndrome Associated Anemia
	1L TD Myelofibrosis Associated Anemia
✦ milvexian (FXIa Inhibitor)	Secondary Stroke Prevention*
	Acute Coronary Syndrome*
	Atrial Fibrillation*
CAMZYOS	Non-obstructive Hypertrophic Cardiomyopathy
✦ cendakimab	Eosinophilic Esophagitis
SOTYKTU	Psoriatic Arthritis
	Systemic Lupus Erythematosus
ZEPOSIA	Crohn's Disease

Registration US, EU, JP

OPDIVO	Neoadjuvant Non-Small Cell Lung Cancer (EU)
	Adj Melanoma stage IIB/C (US, EU)
BREYANZI	2L Large B-cell Lymphoma (EU)
ABECMA (ide-cel)	3-5L Multiple Myeloma (US, EU, JP)
CAMZYOS	Obstructive Hypertrophic Cardiomyopathy (EU)
	Obstructive Hypertrophic Cardiomyopathy SRT eligible (US)

* Partner-run study

✦ NME leading indication

Oncology | Hematology | CV | Fibrosis | Neuroscience | Immunology

Development Partnerships: ABECMA (ide-cel): 2seventy bio; AHR: Ikena Oncology; Anti-Tau: Prothena; CAMZYOS in China, Singapore, Thailand, Macau, HK, Taiwan: LianBio; Claudin 18.2 ADC: LaNova Medicines; CD3xPSCA: Avencell; eIF2b Activator: Evotec; farletuzumab ecteribulin: Eisai; HSP47: Nitto Denko Corporation; rHuPH20: Halozyme; IDHIFA: Servier; MAGEA4/8 TCER: Immatics; milvexian: Janssen Pharmaceuticals, Inc.; OPDIVO, YERVOY, OPDUALAG in Japan: Ono; PKCθ Inhibitor: Exscientia; REBLOZYL: Merck; SHP2 Inhibitor: BridgeBio Pharma; TIGIT Bispecific: Agenus

Changes to the Development Pipeline – Q1 2023

	Phase I	Phase II	Phase III
New or Phase Transition	✦CD19 NEX T in Severe Refractory Systemic Lupus Erythematosus ✦NME in Solid Tumors	✦TYK2 Inhibitor (BMS-986322) in Moderate-to-Severe Psoriasis	✦milvexian in Acute Coronary Syndrome ✦milvexian in Atrial Fibrillation iberdomide Post-Transplant Maintenance Newly Diagnosed Multiple Myeloma
Removed	✦LSD1 Inhibitor iberdomide in lymphoma		✦Subcutaneous nivolumab + rHuPH20 auto-injector in adjuvant melanoma (multi-indications)

Registrational Submissions (n=5)

- OPDIVO in adjuvant melanoma (US/EU)
- ABECMA in 3-5L relapsed or refractory multiple myeloma (US/EU/JP)

Approvals (n=3)

- OPDIVO in neo-adjuvant NSCLC (JP)
- SOTYKTU in moderate-to-severe plaque psoriasis (EU)
- REBLOZYL β-Thalassemia NTD (EU)

✦ NME leading indication

Oncology | Hematology | Immunology | CV | Fibrosis | Neuroscience

Q1 2023 Late-Stage Drug Development Clinical Trials Update

Oncology	Hematology	Cell Therapy	Immunology	Cardiovascular
Opdivo	iberdomide	Breyanzi	cendakimab	milvexian
Opdualag	mezigdomide	Abecma	LPA1 antagonist	Camzyos
repotrectinib	Reblozyl		Sotyktu	
	Onureg		Zeposia	

Opdivo (anti-PD1)

Lung Cancer Trials

Indication	Neoadjuvant NSCLC	Peri-Adjuvant NSCLC	Stage IB-IIIA Adjuvant NSCLC	Stage III Unresectable NSCLC
Phase/Study	Phase III - CheckMate -816	Phase III – CheckMate -77T	Phase III – ANVIL Non-BMS Sponsored*	Phase III - CheckMate -73L
# of Patients	N = 505	N = 452	N = 903	N = 888
Design	• Opdivo 360 mg Q3W for three cycles + PDCT • PDCT	• Neoadjuvant Opdivo + PDCT followed by adjuvant Opdivo • Neoadjuvant placebo + PDCT followed by placebo	• Opdivo Q4W • Observation (patients followed serially with imaging for 1 year)	• Opdivo + CCRT followed by Opdivo + Yervoy • Opdivo + CCRT followed by Opdivo • CCRT followed by durvalumab
Endpoints	• Primary: pCR, EFS	• Primary: EFS • Key secondary: OS	• Primary: DFS, OS	• Primary: PFS • Key secondary: OS
Status	• Presented pCR at AACR 2021 & EFS at AACR 2022 • U.S. FDA approval March 2022 & Japan PMDA approval March 2023 • Application under review in EU • Published in NEJM April 2022	• Projected data readout 2024	• Projected data readout 2024	• Projected data readout 2025
CT Identifier	NCT02998528	NCT04025879	NCT02595944	NCT04026412

*Trial conducted by NCI/ECOG

Opdivo (anti-PD1)

Early-Stage Trials

Indication	Adjuvant Melanoma	Peri-Adjuvant MIUC	Adjuvant HCC
Phase/Study	Phase III – CheckMate -76K – Stage IIB/C	Phase III - CA 017-078	Phase III – CheckMate -9DX
# of Patients	N = 790	N = 861	N = 545
Design	• Opdivo 480 mg Q4W • Placebo	• Opdivo 360 mg Q3W for four cycles + chemotherapy • Chemotherapy	• Opdivo 480 mg Q4W • Placebo
Endpoints	• Primary: RFS • Key secondary: OS	• Primary: pCR, EFS • Key secondary: OS	• Primary: RFS • Key secondary: OS
Status	• Presented as Late Breaker at SMR 2022 • U.S. PDUFA October 13, 2023 • Application under review in the EU	• Projected data readout 2024	• Projected data readout 2025
CT Identifier	NCT04099251	NCT03661320	NCT03383458

Opdivo (anti-PD1)

Metastatic Trials

Indication	1L MIUC	1L mCRPC
Phase/Study	Phase III - CheckMate -901	Phase III - CheckMate-7DX
# of Patients	N = 1,307	N = 984
Design	• PD-L1+ & cis-ineligible: Opdivo + Yervoy w/ Opdivo follow-up vs SOC chemotherapy • Cis-eligible: Opdivo + gemcitabine-cisplatin w/ Opdivo follow-up vs SOC chemotherapy	• Opdivo + docetaxel + prednisone • Placebo + docetaxel + prednisone
Endpoints	Primary: • PFS, OS in cis-eligible patients • OS in PD-L1+ (>=1%) & cis-ineligible	• Primary: rPFS, OS • Key secondary: ORR
Status	• Recruiting • Projected data readout 2023 (cis-eligible) & 2024 (cis-ineligible) • PDL1+ did not meet primary OS endpoint	• Projected data readout 2023
CT Identifier	NCT03036098	NCT04100018

Opdivo (anti-PD1)

Metastatic Trials

Indication	1L HCC	1L+ MSI High CRC	2L RCC SC
Phase/Study	Phase III – CheckMate -9DW	Phase III - CheckMate -8HW	Phase III - CheckMate -67T
# of Patients	N = 732	N = 831	N = 454
Design	• Opdivo + Yervoy • sorafenib/lenvatinib	• Opdivo • Opdivo + Yervoy • Chemotherapy	• Opdivo + rHuPH20 SC • Opdivo IV
Endpoints	• Primary: OS • Key secondary: ORR	Primary: • PFS Arm B vs. A, all lines • PFS Arm B vs. C, first line • Key secondary: ORR, OS	Primary: • Cavgd28 (Opdivo serum concentration) • Cminss • Key secondary: ORR
Status	• Projected data readout 2025	• Projected data readout 2024	• Projected data readout 2023
CT Identifier	NCT04039607	NCT04008030	NCT04810078

Opdualag (anti-LAG3 + anti-PD1 FDC)

Indication	Adjuvant Melanoma	1L Melanoma SC	2L/3L+ MSS mCRC
Phase/Study	Phase III – RELATIVITY-098	Phase III – RELATIVITY-127	Phase III - RELATIVITY-123
# of Patients	N = 1050	N = 814	N = 700
Design	• Relatlimab + nivolumab FDC 160 mg/480 mg Q4W • Nivolumab 480mg Q4W	• Relatlimab + nivolumab + rHuPH20 FDC SC • Relatlimab + nivolumab FDC IV	• Relatlimab + nivolumab FDC • Investigator's Choice: regorafenib or TAS-102 (trifluridine/tipiracil)
Endpoints	• Primary: RFS • Key secondary: OS	Primary: • Cavgd28 of nivolumab; Cminss of nivolumab • Cavgd28 of relatlimab; Cminss of relatlimab • Key secondary: ORR	Primary : • OS in PD-L1 CPS≥1 • OS in all-comers • Key secondary: ORR
Status	• Projected data readout 2026	• Recruiting • Projected data readout 2025	• Recruiting • Projected data readout 2025
CT Identifier	NCT05002569	NCT05625399	NCT05328908

Opdualag (anti-LAG3 + anti-PD1 FDC)

Indication	1L HCC	2L+ HCC (Post TKI)	1L Stage IV NSCLC
Phase/Study	Phase I/II - RELATIVITY-106	Phase II - CA224-073	Phase II - CA224-104
# of Patients	N = 162	N = 250	N = 420
Design	• Nivolumab + relatlimab + bevacizumab • Nivolumab + placebo + bevacizumab	• Nivolumab + relatlimab Dose 1 • Nivolumab + relatlimab Dose 2 • Nivolumab	Part I: • Nivolumab + relatlimab Dose 1 + PDCT • Nivolumab + relatlimab Dose 2 + PDCT Part II: • Nivolumab + relatlimab Dose 2 + PDCT • Nivolumab + PDCT
Endpoints	Primary: DLTs, PFS	• Primary: ORR	Primary: • Part I: TRAEs leading to discontinuation within 12 weeks after first dose • Part II: ORR
Status	• Recruiting • Projected data readout 2024	• Projected data readout 2024	• Recruiting • Projected data readout YE 2023/2024
CT Identifier	NCT05337137	NCT04567615	NCT04623775

repotrectinib (ROS1/NTRK)

Indication	ROS1 NSCLC & NTRK+ Solid Tumors
Phase/Study	Phase I/II – TRIDENT-1
# of Patients	N = 500
Design	Phase I: • Dose escalation; food-effect, dose escalation with food; & Midazolam DDI Phase II: Expansion cohorts • ROS1 TKI-naïve ROS1+ NSCLC 160 mg QD for the first 14 days, then 160 mg BID[a] • 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC • 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or I-O) • 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or I-O) • TRK TKI-naïve NTRK+ solid tumors • TRK TKI-pretreated NTRK+ solid tumors
Endpoints	Primary: • Phase I: DLTs, RP2D • Phase II: ORR
Status	• Recruiting • Projected data readout 2023
CT Identifier	NCT03093116

[a]Based on tolerability

iberdomide (CELMoD)

Indication	2L+ MM	Post-Transplant Maintenance NDMM
Phase/Study	Phase III – EXCALIBER	Phase III – EXCALIBER-Maintenance
# of Patients	N = 864	N = 1,216
Design	• Iberdomide 1.0, 1.3,1.6 mg + daratumumab 1800 mg + dex 40 mg - (iberDd) • Daratumumab 1800 mg + bortezomib 1.3 mg/m2[a] + dex 20 mg[a] - (DVd)	• Iberdomide Dose 1 • Iberdomide Dose 2 • Iberdomide Dose 3 • Lenalidomide
Endpoints	• Primary: PFS • Key secondary: OS	• Primary: PFS • Key Secondary: MRD, OS
Status	• Recruiting • Projected data readout 2027	• Trial initiating • Projected data readout 2029
CT Identifier	NCT04975997	NCT05827016

[a]BIW dosing

mezigdomide (CELMoD)

Indication	2L+ MM	2L+ MM
Phase/Study	Phase III – SUCCESSOR-1	Phase III – SUCCESSOR-2
# of Patients	N = 810	N = 575
Design	• Mezigdomide 0.3, 0.6, 1.0 mg + bortezomib 1.3 mg/m2[a] + dex 20 mg - (MeziVd) • Pomalyst 4 mg + bortezomib 1.3 mg/m2[a] + dex 20 mg - (PVd)	• Mezigdomide 0.3, 0.6, 1.0 mg + carfilzomib 56 mg/m2[b] + dex 40 mg [b] - (MeziKd) • Carfilzomib 56 mg/m2[a] + dex 20 mg[a] - (Kd)
Endpoints	• Primary: PFS • Key secondary: OS	• Primary: PFS • Key secondary: OS
Status	• Recruiting • Projected data readout 2026	• Recruiting • Projected data readout 2026
CT Identifier	NCT05519085	NCT05552976

[a] BIW dosing; [b] QW dosing

Reblozyl (Erythroid Maturation Agent)

Indication	1L TD Myelodysplastic Syndrome (MDS) Associated Anemia	1L TD Myelofibrosis (MF) Associated Anemia	TD & NTD Alpha-Thalassemia (Ex-US study)
Phase/Study	Phase III - COMMANDS	Phase III - INDEPENDENCE	Phase II - CA056-015
# of Patients	N = 362	N = 309	N = 177
Design	• Reblozyl 1.0 mg/kg SC Q3W • Epoetin Alfa 450 IU/kg SC QW	• Reblozyl 1.33 mg/kg SC Q3W + Best Supportive Care • Placebo SC Q3W + Best Supportive Care	• Reblozyl 1.0 mg/kg SC Q3W • Placebo SC Q3W + Best Supportive Care
Endpoints	• RBC-TI for 12 weeks with a mean hemoglobin increase ≥ 1.5 g/dL through week 24	• Primary: RBC-TI during any consecutive 12-week period starting within the first 24 weeks • Key secondary: RBC-TI ≥ 16 weeks (RBC-TI 16)	Primary: • TD: ≥50% reduction in TF burden over any rolling 12 weeks between W13-W48 • NTD: ≥1 g/dL Hb mean increase from baseline in W13-W24 Key secondary: • TD: No. of participants with ≥ 33% reduction from baseline in RBC transfusion burden • NTD: Change from baseline to W24 in hemoglobin in the absence of transfusion
Status	• Positive topline results in October 2022 • Data to be presented at ASCO & EHA 2023	• Recruiting • Expected data readout 2025	• Recruiting • Expected data readout 2025
CT Identifier	NCT03682536	NCT04717414	NCT05664737

Onureg (Hypomethylating Agent)

Indication	(IPSS-R) Low-or Intermediate Risk MDS
Phase/Study	Phase II/III – METEOROID
# of Patients	N = 230
Design	• Onureg 200 mg, 300 mg in Phase II + Best Supportive Care • Onureg RP3D in Phase III + Best Supportive Care • Placebo
Endpoints	Primary: • Safety & Tolerability & RP3D (Phase II) • Achieved Complete Remission per IWG 2006 within 6 cycles (Phase II & III) Key Secondary: • 84-day pRBC TI (Phase II & III)
Status	• Recruiting • Projected data readout 2026
CT Identifier	NCT05469737

Breyanzi (CD 19 CAR T)

Indication	2L LBCL TE	R/R iNHL	3L+ CLL
Phase/Study	Phase III – TRANSFORM	Phase II – TRANSCEND FL	Phase II – TRANSCEND CLL
# of Patients	N = 184	N = 213	N = 209
Design	• Breyanzi • SOC (R-DHAP, R-ICE or R-GDP)	• Breyanzi iNHL includes 3L+ FL, 2L FL (high risk), 3L+ MZL	• Breyanzi • Breyanzi + ibrutinib • Breyanzi + venetoclax
Endpoints	• Primary: EFS	• Primary: ORR	• Primary: CRR
Status	• U.S. FDA approval June 2022 & Japan PMDA December 2022 • EU CHMP Positive Opinion • Published in Lancet June 2022 & in Blood December 2022 • Data presented at ASH 2022	• Recruiting • Projected data readout 2023 in 2L (high risk), 3L+ FL • Projected data readout 2025 in 3L+ MZL	• Met primary endpoint in monotherapy arm in January 2023 • Data to be presented at ASCO 2023
CT Identifier	NCT03575351	NCT04245839	NCT03331198

Abecma (BCMA CAR T)

Indication	1L-4L+ MM	3L-5L MM
Phase/Study	Phase II – KarMMa-2	Phase III – KarMMa-3
# of Patients	N = 235	N = 381
Design	• Cohort 1: ≥ 3 prior regimens • Cohort 2a: 1L with ASCT & relapsed within 18 months • Cohort 2b: 1L excluding ASCT & relapsed within 18 months • Cohort 2c: inadequate response post ASCT during initial treatment • Cohort 3: inadequate response post ASCT, with Revlimid maintenance therapy	• Abecma • Standard regimens as per Investigator's discretion – DPd, DVd, IRd, Kd, EPd
Endpoints	• Primary: ORR, CRR	• Primary: PFS • Key secondary: OS
Status	• Recruiting • Data presented at ASH 2022 on cohorts 2a and 2c	• Data presented at EHA EBMT 2023 • Published in NEJM February 2023 • U.S. PDUFA December 16, 2023 • Application under review in EU & Japan
CT Identifier	NCT03601078	NCT03651128

cendakimab (anti-IL13)

Indication	Eosinophilic Esophagitis (EoE)
Phase/Study	Phase III - CC-93538-EE-001
# of Patients	N = 399
Design	• Cendakimab 360 mg SC QW for 24 wks, followed by 360 mg SC QW for 24 wks • Cendakimab 360 mg SC QW for 24 wks, followed by 360 mg SC Q2W for 24 wks • Placebo
Endpoints	• Change in Dysphagia Days (Clinical Response) at Week 24 • Eosinophil Histologic Response (≤ 6/hpf) at Week 24
Status	• Recruiting • Expected data readout 2024
CT Identifier	NCT04753697

LPA_1 antagonist

Indication	Pulmonary Fibrosis
Phase/Study	Phase II – IM027-040
# of Patients	N = 373
Design	Cohort 1 IPF: • LPA_1 30 mg BID + post treatment follow-up or optional treatment extension • LPA_1 60 mg BID + post treatment follow-up or optional treatment extension • IPF Placebo + post treatment follow-up or optional treatment extension Cohort 2 PPF: • LPA_1 30 mg BID + post treatment follow-up or optional treatment extension • LPA_1 60 mg BID + post treatment follow-up or optional treatment extension • PF-ILD (PPF) Placebo + post treatment follow-up or optional treatment extension
Endpoints	• Rate of change in percent predicted forced vital capacity (ppFVC) in IPF participants
Status	• Achieved PoC in IPF in 2022 • IPF data to be presented as Late Breaker at ATS 2023 • PPF expected data readout in 2023
CT Identifier	NCT04308681

Sotyktu (TYK-2 inhibitor)

Indication	Alopecia Areata (AA)
Phase/Study	Phase II – IM011-134
# of Patients	N = 90
Design	• Sotyktu Dose 1 • Sotyktu Dose 2 • Placebo, followed by Sotyktu Dose 1 or Dose 2
Endpoints	• Change from baseline in SALT score at Week 24
Status	• Recruiting • Expected data readout 2024
CT Identifier	NCT05556265

Sotyktu (TYK-2 inhibitor)

Indication	Psoriatic Arthritis (PsA)	
Phase/Study	Phase III - POETYK-PsA-1	Phase III - POETYK-PsA-2
# of Patients	N = 650	N = 700
Design	52-week study of patients with active PsA in TNF-naïve patients • Sotyktu 6 mg QD • Placebo	52-week study of patients with active PsA in TNF-naïve and TNF-IR patients • Sotyktu 6 mg QD • Placebo • Apremilast
Endpoints	• % pts achieving ACR20 response at Week 16	• % pts achieving ACR20 response at Week 16
Status	• Recruiting • Expected data readout 2025 (52 wks)	• Recruiting • Expected data readout 2024 (52 wks)
CT Identifier	NCT04908202	NCT04908189

Sotyktu (TYK-2 inhibitor)

Indication	Systemic Lupus Erythematosus (SLE)		Discoid Lupus Erythematosus (DLE)
Phase/Study	Phase III - POETYK SLE-1	Phase III - POETYK SLE-2	Phase II - IM011-132
# of Patients	N = 490	N = 490	N = 75
Design	• Sotyktu • Placebo	• Sotyktu • Placebo	52-week study: • Sotyktu Dose A • Sotyktu Dose B • Placebo
Endpoints	• Proportion of participants who meet response criteria SRI-4 at week 52	• Proportion of participants who meet response criteria SRI-4 at week 52	• Change from baseline in CLASI-A activity score at week 16
Status	• Recruiting • Expected data readout 2026	• Recruiting • Expected data readout 2026	• Recruiting • Expected data readout 2025
CT Identifier	NCT05617677	NCT05620407	NCT04857034

Sotyktu (TYK2 inhibitor)

Indication	Crohn's Disease (CD) Moderate to Severe	Ulcerative Colitis (UC) Moderate to Severe
Phase/Study	Phase II - LATTICE-CD	Phase II – IM011-127
# of Patients	N = 241	N = 50
Design	• Sotyktu Dose A • Sotyktu Dose B • Placebo	• Sotyktu (High Dose) • Placebo
Endpoints	• Proportion of pts achieving clinical remission at week 12 • Proportion of pts achieving endoscopic response at week 12	• Proportion of participants in clinical response at Week 12
Status	• POC not achieved; awaiting higher dose UC Ph2 data to inform future IBD development plans	• Expected data readout in 2H 2023
CT Identifier	NCT03599622	NCT04613518

Zeposia (S1P agonist)

Indication	YELLOWSTONE Program: Crohn's Disease (CD) - Moderate to Severe		
Phase/Study	Phase III - RPC01-3201 (Induction 1)	Phase III - RPC01-3202 (Induction 2)	Phase III - RPC01-3203 (Maintenance)
# of Patients	N = 600	N = 600	N = 485
Design	• Zeposia 0.92 mg QD • Placebo	• Zeposia 0.92 mg QD • Placebo	• Zeposia 0.92 mg QD • Placebo
Endpoints	• Proportion of pts in clinical remission (CDAI* score < 150) at week 12	• Proportion of pts in clinical remission (CDAI* score < 150) at week 12	• Proportion of pts in clinical remission (CDAI score of < 150) at week 52 • Proportion of pts with a Simple Endoscopic Score for Crohn's Disease (SES-CD) decrease of ≥ 50% at week 52
Status	• Recruiting • Expected data readout 2024	• Recruiting • Expected data readout 2024	• Recruiting • Expected data readout 2025 (52 wks post induction & basis for filing)
CT Identifier	NCT03440372	NCT03440385	NCT03464097

milvexian (FXIa inhibitor)

Indication	Secondary Stroke Prevention	Acute Coronary Syndrome	Non-Valvular Atrial Fibrillation
Phase/Study	Phase III – LIBREXIA-STROKE Non-BMS Sponsored*	Phase III – LIBREXIA-ACS Non-BMS Sponsored*	Phase III – LIBREXIA-AF Non-BMS Sponsored*
# of Patients	N = 15,000	N = 16,000	N = 15,500
Design	• Milvexian 25 mg BID + background antiplatelet therapy • Placebo + background antiplatelet therapy	• Milvexian + background antiplatelet therapy • Placebo + background antiplatelet therapy Note: participants enrolled within 7 days of ACS +/- catheterization	• Milvexian • Eliquis
Endpoints	• Primary: Time to first occurrence of ischemic stroke Key secondary: • Time to first occurrence of any component of the composite of CVD, MI, or ischemic stroke • Time to first occurrence of ischemic stroke	• Primary: Time to first occurrence of MACE • Key secondary: Time to first occurrence of any component of the composite of MAVE	• Primary: Time to first occurrence of composite endpoint of stroke & non-CNS system embolism Key secondary: • Time to first occurrence of ISTH major bleeding • Time to first occurrence of the composite of ISTH major & CRNM bleeding
Status	• Recruiting • Projected data readout 2026 (event driven)	• Recruiting • Projected data readout 2026 (event driven)	• Recruiting • Projected data readout 2027 (event driven)
CT Identifier	NCT05702034	NCT05754957	NCT05757869

*Trials conducted by Janssen

Camzyos (myosin inhibitor)

Indication	Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)		Heart Failure with Preserved Ejection Fraction (HFpEF)	Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Phase/Study	Phase III - EXPLORER	Phase III - VALOR	Phase II - EMBARK	Phase III - ODYSSEY-HCM
# of Patients	N = 251	N = 110	N = 35	N = 420
Design	• Camzyos 2.5mg, 5mg, 10mg, 15mg QD • Placebo	• Camzyos 2.5mg, 5mg, 10mg, 15mg QD • Placebo	• Camzyos	• Camzyos • Placebo
Endpoints	• Primary: Composite of improvement of Peak VO2 and reduction of one or more class in NYHA function	Primary: • SRT status • Number of subjects who decide to proceed with SRT prior to or at Week 16 and the number of subjects who remain guideline eligible for SRT at Week 16	Primary: • TEAEs and SAEs • Effect on NT-proBNP levels • Effect on cTnT levels (at rest)	Primary: • Change from baseline in Clinical Summary Score (KCCQ-23 CSS) at Week 52 • Change from baseline in peak oxygen consumption (pVO2) at Week 52 Secondary: Change from baseline in VE/VCO2 slope to Week 52
Status	• Published in Lancet 2020 • Presented at HFSA & AHA 2021 & ACC 2022 • U.S. FDA approval April 2022 • EU CHMP Positive Opinion	• Published in JACC July 2022 • Presented at ACC 2022 • U.S. PDUFA June 16, 2023 • Application under review in EU	• Recruiting • Projected data readout 2023/2024	• Recruiting • Projected data readout 2025
CT Identifier	NCT03470545	NCT04349072	NCT04766892	NCT05582395

Abbreviations

AA	Alopecia Areata
AACR	American Association for Cancer Research
Adj	Adjuvant
AE	Adverse Event
AHA	American Heart Association
AML	Acute Myeloid Leukemia
ASH	American Society of Hematology
BCMA	B-Cell Maturation Antigen
BID	Twice a Day
BIW	Twice a Week
CAR T	Chimeric Antigen Receptor Therapy
CCRT	Concurrent Chemoradiation Therapy
CD	Crohn's Disease
CDAI	Crohn's Disease Activity Index
CLL	Chronic Lymphocytic Leukemia
CM	Checkmate
CR	Complete Response
CRR	Complete Remission Rate
CRC	Colorectal Cancer
DFS	Disease-free survival
DLBCL	Diffuse Large B-Cell Lymphoma
DLE	Discoid Lupus Erythematosus
DLT	Dose Limiting Toxicity
EADV	European Academy of Dermatology and Venereology
EASI	Eczema Area & Severity Index
EFS	Event Free Survival
EoE	Eosinophilic Esophagitis
ESA	Erythropoietin Stimulating Agents
ESCC	Esophageal Squamous Cell Carcinoma
FDC	Fixed Dose Combination
FDA	Food & Drug Administration
FL	Follicular Lymphoma
Hb	Hemoglobin
HCC	Hepatocellular Carcinoma
HFpEF	Heart Failure w/ Preserved Ejection Fraction
iNHL	Indolent Non-Hodgkin's Lymphoma
I-O	Immuno-Oncology
IPSS-R	International Prognostic Scoring System
IV	Intravenous
LBCL	Large B-Cell Lymphoma
LVOT	Left Ventricular Outflow Tract
mCRPC	Metastatic Castration-Resistant Prostate Cancer
MDS	Myelodysplastic Syndrome
mDSD	modified Daily Symptom Diary
Mel	Melanoma
MF	Myelofibrosis
MIUC	Muscle Invasive Urothelial Cancer
MM	Multiple Myeloma
MR	Minimal Response
MS	Multiple Sclerosis
MSI-H	High Microsatellite Instability
MSS	Microsatellite Stable
MTD	Maximum Tolerated Dose
MZL	Marginal Zone Lymphoma
nHCM	Non-Obstructive Hypertrophic Cardiomyopathy
ND	Newly Diagnosed
NSCLC	Non-Small Cell Lung Cancer
NTD	Non-Transfusion Dependent
NTRK	Neurotrophic Tyrosine Receptor Kinase
NYHA	New York Health Association
oHCM	Obstructive Hypertrophic Cardiomyopathy
ORR	Overall Response Rate
OS	Overall Survival
PASI	Psoriasis Area and Severity Index
pCR	Pathological Complete Response
PDCT	Platinum-Based Chemotherapy
PDL	Programmed Death Ligand
PDUFA	Prescription Drug User Fee Act
PF	Pulmonary Fibrosis
PFS	Progression Free Survival
POC	Proof of Concept
PsA	Psoriatic Arthritis
PsO	Psoriasis
QD	Once Daily
QW	Once Weekly
RBC-TI	Red Blood Cell Transfusion Independence
RCC	Renal Cell Carcinoma
RFS	Recurrence-free survival
RP2D	Recommended Phase 2 Dose
RP3D	Recommended Phase 3 Dose
ROS	C-ROS Oncogene
RR	Relapsed Refractory
SAE	Serious Adverse Event
SC	Subcutaneous
SCT	Stem Cell Transplant
SLE	Systemic Lupus Erythematosus
SoC	Standard of Care
sPGA	Static Physicians Global Assessment
SRI	Systemic Lupus Responder Index
SRT	Septal Reduction Therapy
SSP	Secondary Stroke Prevention
SubQ/SC	Subcutaneous
TD	Transfusion Dependent
TE	Transplant Eligible
TEAE	Treatment Emergent Adverse Events
TKI	Tyrone Kinase Inihibitor
TRAE	Treatment Related Adverse Events
TE	Transplant Eligible
TNF	Tumor Necrosis Factor
UC	Ulcerative Colitis
VO2	Volume of Oxygen